Guidance and Visibility Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility

AAPL 272.55

-0.1%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keithcray who wrote (10007)	8/8/2001 3:23:59 PM
From: 2MAR$	Read Replies (1) of 208838

yup , added some longs DJ Teva Pharma/FDA -2: For 15mg Buspirone Tablets >TEVA NEW YORK (Dow Jones)--Teva Pharmaceutical Industries Ltd. (TEVA) received tentative approval for 15-milligram Buspirone HCL Tablets from the Food and Drug Administration. Buspirone HCL tablets are the generic version of Bristol- Myers Squibb Co.'s (BMY) Buspar for the treatment of anxiety with depression. Teva said annual sales of the 15mg brand in the U.S. are estimated at $395 million. In a press release Wednesday, the Israel-based pharmaceutical company said it now has tentative approvals for 5mg, 10mg and 15mg of Buspirone HCL tablets. Currently other competitors have the rights to an exclusive marketing period, which will end at the end of September, after which multiple competitors may enter the market, Teva said. Teva shares recently traded at $69.35, up $1.90, or 2.8%, on Nasdaq volume of 431,300 shares. Average daily volume is 1.1 million share

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next